Chinchialak!!!!!!! kopi at market this morning full
kopishit.. old unca server said kopi net broke.
-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
Breaking News!!!Giant Deadly Scam???
- Thread starter kopiuncle
- Start date
Chinchialak!!!!!!! kopi at market this morning full
kopishit.. old unca server said kopi net broke.
..........................
Hahahahaha! Kopisai angry leow!
Hey, are you sure the two are your nieces and not your xiao long nu?
chi la kak people like you are best ignored...haha!! PU Bor Kia!!!
hahaha you kana conned lah!!!!
read this:
http://www.snopes.com/medical/drugs/gardasil.asp
so now are you happy to have the jabs???
Acs, N., Bata, Z., Danko, D., Hernádi, Z., Kálmán, M., Kornya, L., Kovács, J., Mézáros, G., Molnár, M.P., Mór, Z., Novák, Z., Sobel, G., Szentirmay, Z., Takács, L., Tisza, T., 2012. [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention]. Orv Hetil 153 Suppl, 3–38.
Asiaf, A., Ahmad, S.T., Mohammad, S.O., Zargar, M.A., 2013. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur. J. Cancer Prev.
Bősze, P., 2013. [The first vaccine against cancer: the human papillomavirus vaccine]. Orv Hetil 154, 603–618.
De Vincenzo, R., Ricci, C., Conte, C., Scambia, G., 2013. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol. Oncol. 130, 642–651.
Denny, L., Hendricks, B., Gordon, C., Thomas, F., Hezareh, M., Dobbelaere, K., Durand, C., Hervé, C., Descamps, D., 2013. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study. Vaccine 31, 5745–5753.
Donegan, K., Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., Bryan, P., 2013. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31, 4961–4967.
Draper, E., Bissett, S.L., Howell-Jones, R., Waight, P., Soldan, K., Jit, M., Andrews, N., Miller, E., Beddows, S., 2013. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS ONE 8, e61825.
Esselen, K.M., Feldman, S., 2013. Cost-effectiveness of cervical cancer prevention. Clin Obstet Gynecol 56, 55–64.
Farhath, S., Vijaya, P.P., Mumtaj, P., 2013. Cervical cancer: is vaccination necessary in India? Asian Pac. J. Cancer Prev. 14, 2681–2684.
Han, K.T., Sin, J.-I., 2013. DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin Exp Vaccine Res 2, 106–114.
Holt, H., Hinkle, D.M., Falk, N.S., Fraunfelder, F.T., Fraunfelder, F.W., 2013. Human Papilloma Virus Vaccine Associated Uveitis. Curr Drug Saf.
Howell-Jones, R., Soldan, K., Wetten, S., Mesher, D., Williams, T., Gill, O.N., Hughes, G., 2013. Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J. Infect. Dis. 208, 1397–1403.
Mesher, D., Soldan, K., Howell-Jones, R., Panwar, K., Manyenga, P., Jit, M., Beddows, S., Gill, O.N., 2013. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine.
Nelson, E.A.S., Lam, H.S., Choi, K.C., Ho, W.C.S., Fung, L.W.E., Cheng, F.W.T., Sung, R.Y.T., Royals, M., Chan, P.K.S., 2013. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine 31, 3452–3460.
Russell, M., Raheja, V., Jaiyesimi, R., 2013. Human papillomavirus vaccination in adolescence. Perspect Public Health 133, 320–324.
Spila-Alegiani, S., Da Cas, R., Giambi, C., Raschetti, R., Salmaso, S., 2013. [Human papillomavirus vaccine register]. Recenti Prog Med 104, 262–266.
Verdenius, I., Groner, J.A., Harper, D.M., 2013. Cross protection against HPV might prevent type replacement. Lancet Infect Dis 13, 195.
Wang, J.W., Roden, R.B.S., 2013. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines 12, 129–141.
Wong, M.C.S., Lee, A., Ngai, K.L.K., Chor, J.C.Y., Chan, P.K.S., 2013. Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS ONE 8, e71827.
Zhang, C., Gotsis, M., Jordan-Marsh, M., 2013. Social media microblogs as an HPV vaccination forum. Hum Vaccin Immunother 9.
Asiaf, A., Ahmad, S.T., Mohammad, S.O., Zargar, M.A., 2013. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur. J. Cancer Prev.
Bősze, P., 2013. [The first vaccine against cancer: the human papillomavirus vaccine]. Orv Hetil 154, 603–618.
De Vincenzo, R., Ricci, C., Conte, C., Scambia, G., 2013. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol. Oncol. 130, 642–651.
Denny, L., Hendricks, B., Gordon, C., Thomas, F., Hezareh, M., Dobbelaere, K., Durand, C., Hervé, C., Descamps, D., 2013. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study. Vaccine 31, 5745–5753.
Donegan, K., Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., Bryan, P., 2013. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31, 4961–4967.
Draper, E., Bissett, S.L., Howell-Jones, R., Waight, P., Soldan, K., Jit, M., Andrews, N., Miller, E., Beddows, S., 2013. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS ONE 8, e61825.
Esselen, K.M., Feldman, S., 2013. Cost-effectiveness of cervical cancer prevention. Clin Obstet Gynecol 56, 55–64.
Farhath, S., Vijaya, P.P., Mumtaj, P., 2013. Cervical cancer: is vaccination necessary in India? Asian Pac. J. Cancer Prev. 14, 2681–2684.
Han, K.T., Sin, J.-I., 2013. DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin Exp Vaccine Res 2, 106–114.
Holt, H., Hinkle, D.M., Falk, N.S., Fraunfelder, F.T., Fraunfelder, F.W., 2013. Human Papilloma Virus Vaccine Associated Uveitis. Curr Drug Saf.
Howell-Jones, R., Soldan, K., Wetten, S., Mesher, D., Williams, T., Gill, O.N., Hughes, G., 2013. Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J. Infect. Dis. 208, 1397–1403.
Mesher, D., Soldan, K., Howell-Jones, R., Panwar, K., Manyenga, P., Jit, M., Beddows, S., Gill, O.N., 2013. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine.
Nelson, E.A.S., Lam, H.S., Choi, K.C., Ho, W.C.S., Fung, L.W.E., Cheng, F.W.T., Sung, R.Y.T., Royals, M., Chan, P.K.S., 2013. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine 31, 3452–3460.
Russell, M., Raheja, V., Jaiyesimi, R., 2013. Human papillomavirus vaccination in adolescence. Perspect Public Health 133, 320–324.
Spila-Alegiani, S., Da Cas, R., Giambi, C., Raschetti, R., Salmaso, S., 2013. [Human papillomavirus vaccine register]. Recenti Prog Med 104, 262–266.
Verdenius, I., Groner, J.A., Harper, D.M., 2013. Cross protection against HPV might prevent type replacement. Lancet Infect Dis 13, 195.
Wang, J.W., Roden, R.B.S., 2013. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines 12, 129–141.
Wong, M.C.S., Lee, A., Ngai, K.L.K., Chor, J.C.Y., Chan, P.K.S., 2013. Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. PLoS ONE 8, e71827.
Zhang, C., Gotsis, M., Jordan-Marsh, M., 2013. Social media microblogs as an HPV vaccination forum. Hum Vaccin Immunother 9.
erection2015
Alfrescian (InfP) + C
it does sound terrible...but if BosSam can survive it then so can we.
not when tongue, throat, clit, cervix, penis all kenna.
that wasn't hpv 69. it was hps 495. help pay subscription at $4.95. :p
Last edited:
Similar threads
